Olema Pharmaceuticals Inc... (OLMA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
5.43
0.29 (5.64%)
At close: Jan 15, 2025, 1:58 PM
Ratios (Annual)
Discover comprehensive ratio statement breakdowns that reveal insights into revenue, expenses, and beyond.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
PE Ratio | -6.57 | -0.96 | -5.22 | -83.03 | -456.05 | -314.44 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 2.50 | 0.50 | 1.30 | 5.59 | -185.8 | -110.04 |
P/FCF Ratio | -7.58 | -1.19 | -7.08 | -94.87 | -638.86 | -317.48 |
P/OCF Ratio | -7.58 | -1.19 | -7.3 | -95.13 | -638.86 | -317.48 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | n/a | n/a | n/a |
Quick Ratio | 12.33 | 12.64 | 31.89 | 74.62 | 0.07 | 16.13 |
Current Ratio | 12.33 | 12.62 | 31.85 | 74.62 | 0.07 | 16.13 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | -32.97 | n/a | -74.25 |
Return on Equity (ROE) | -0.38 | -0.52 | -0.25 | -0.07 | 0.41 | 0.35 |
Return on Assets (ROA) | -0.35 | -0.48 | -0.24 | -0.07 | -32.7 | -0.67 |
Return on Capital (ROIC) | -0.41 | -0.54 | -0.25 | -0.06 | 3.47 | -0.68 |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |